Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta blockers and cardiac decompensation].

G M Puddu1, E Cravero, P Puddu

  • 1Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Università degli Studi di Bologna, Italia.

La Clinica Terapeutica
|April 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanical properties and metallurgical features of new and ex vivo used Reciproc Blue and Reciproc.

International endodontic journal·2019
Same author

Clinical predictors of fever in stroke patients: relevance of nasogastric tube.

Acta neurologica Scandinavica·2015
Same author

Skin reactions triggered by the use of cosmetic products in nonspecific lipid transfer protein-sensitive patients.

International journal of immunopathology and pharmacology·2011
Same author

A simple scoring system for outcome prediction of ischemic stroke.

Acta neurologica Scandinavica·2011
Same author

[Job satisfaction, burnout and stress amongst nursing staff: a survey in two hospitals in Rome].

Giornale italiano di medicina del lavoro ed ergonomia·2008
Same author

Mental health in patients with systemic sclerosis: a controlled investigation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2008
Same journal

Effectiveness of Focal Muscle Vibration in Post-Anterior Cruciate Ligament Reconstruction Rehabilitation: A Case Report.

La Clinica terapeutica·2026
Same journal

Violence Against Women as a Public-Health Exposure: Biological Embedding, Medico-Legal Caution and Precision Prevention in the EpiWe Framework.

La Clinica terapeutica·2026
Same journal

Suicide of the Work-Disabled Individual Affected by Neoplasia with Unfavorable Prognosis: Evidence-Based Legal Medicine in Reconstructing the Causal Link.

La Clinica terapeutica·2026
Same journal

The therapeutic potential of N-acetylcysteine across multiple organ systems: a narrative review.

La Clinica terapeutica·2026
Same journal

Mesotherapy in Pain Management in Primary Care: A Narrative Review and Practice-Oriented Appraisal.

La Clinica terapeutica·2026
Same journal

Bone Marrow Edema in Rheumatic Diseases: Incidence, Diagnosis, and Therapeutic Implications. A Narrative Review.

La Clinica terapeutica·2026
See all related articles

Beta blockers improve chronic heart failure by stabilizing hemodynamics and reducing mortality. Third-generation beta blockers offer improved side effect profiles compared to older versions.

Area of Science:

  • Pharmacology
  • Cardiology

Context:

  • Chronic heart failure (CHF) management.
  • Role of sympathoadrenergic activation and the renin-angiotensin-aldosterone system in CHF.
  • Existing beta blocker therapies.

Purpose:

  • To review the role of beta blockers in chronic heart failure.
  • To highlight the characteristics of third-generation beta blockers.
  • To discuss the individualized selection of beta blockers for CHF patients.

Summary:

  • Beta blockers are crucial in managing chronic heart failure by reducing hemodynamic instability and mortality.
  • Third-generation beta blockers (carvedilol, nebivolol, bucindolol) demonstrate an improved side effect profile compared to first-generation agents.
  • Optimal patient outcomes in CHF necessitate tailoring beta blocker selection based on individual pharmacologic profiles and clinical situations.

Related Experiment Videos

Impact:

  • Provides insights into the therapeutic benefits of beta blockers in CHF.
  • Emphasizes the advantages of newer generation beta blockers.
  • Guides clinical decision-making for personalized heart failure treatment.